Synapse - Hematologic Malignancies, Division of

Results (13379)

High complete metabolic response rates with epcoritamab + R‐CHOP in previously untreated (1L) high‐risk DLBCL, including double‐hit/triple‐hit: EPCORE NHL‐2 update

Meeting Abstract

Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

BRCA1/2 mutations impact on the development of breast implant‐associated lymphoma (BIA‐ALCL) in women with breast cancer reconstructed with textured breast implants

Meeting Abstract

Ghione, P.; Arcila, M.; Joseph, V.; Dogan, A.; Cordeiro, P.; Salles, G.; de Jong, D.; Horwitz, S.; Mandelker, D.; van Leeuwen, F.
Hematological Oncology (2023)

Fulltext@MSK | Save

Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma

Meeting Abstract

Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Circulating tumor DNA (CTDNA) status and clinical outcomes in patients (PTS) with previously untreated diffuse large B‐cell lymphoma (DLBCL) in the POLARIX study

Meeting Abstract

Herrera, A. F.; Tracy, S.; Sehn, L. H.; Jardin, F.; Lenz, G.; Trněný, M.; Salles, G.; Flowers, C. R.; Tilly, H.; Sharman, J. P.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Chromatin accessibility profiling to increase diagnostic accuracy and refine cell‐of‐origin classification of mature T‐cell lymphomas

Meeting Abstract

Julia, E.; Mareschal, S.; Chebel, A.; Camille, G.; Missaglia, E.; Rattina, V.; Lours, C.; Testard, Q.; Tschantz, M.; Sebai, S.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL): Extended follow‐up and landmark analyses from a pivotal phase II study

Meeting Abstract

Dickinson, M.; Carlo‐Stella, C.; Morschhauser, F.; Falchi, L.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez‐Lopez, J.; Bartlett, N.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Bispecific anti‐CD20/19 CAR‐T—zamtocabtagene autoleucel for relapsed/refractory DLBCL—Interim analysis results of DALY‐II‐USA study

Meeting Abstract

Ulrickson, M.; Miklos, D. B.; Maziarz, R. T.; Jacobson, C.; Isufi, I.; Ghosh, M.; Perales, M.; Lunning, M.; Hardy, N. M.; Wijatyk, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Pirtobrutinib in covalent BTK‐inhibitor pre‐treated mantle cell lymphoma: Updated results, subgroup analysis from bruin with >3 years follow‐up from start of enrollment

Meeting Abstract

Cheah, C. Y.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I.; Alencar, A. J.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Durables responses with anti‐CD19 allogeneic CAR T ALLO‐501/501A in phase 1 trials of relapsed/refractory large B‐cell lymphoma (R/R LBCL)

Meeting Abstract

Locke, F. L.; Lekakis, L.; Eradat, H.; Munoz, J.; Tees, M.; de Vos, S.; Nath, R.; Stevens, D.; Malik, S.; Popplewell, L.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome

Meeting Abstract

Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save